Clinical Trial Update: A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated [Phase 4]

View source ↗

Summary

Phase 4 non-inferiority trial assessing dose reduction of adalimumab in psoriasis patients who are overtreated has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Psoriasis | Phase 4 | Status: COMPLETED